Contraline, a pioneering biotechnology firm backed by Google Ventures, has successfully closed a substantial $92.5 million Series B financing round.…
Read More
Eli Lilly’s Retatrutide Demonstrates Unprecedented Weight Loss with Notable Side Effect Profile in Phase 3 Trials
Eli Lilly and Company’s investigational drug, retatrutide, a groundbreaking triple hormone receptor agonist, has delivered an average weight loss of…
Read More
Scaling GLP-1 Obesity Trials Without Losing DXA Data
The explosive growth of global obesity trials, fueled by the success of GLP-1 receptor agonist therapies, presents a critical challenge:…
Read More
Saudi Arabia Ascends as a Premier Middle Eastern Hub for Clinical Trials Fueled by Strategic Investment and Infrastructure Development
Saudi Arabia is rapidly solidifying its position as the preeminent growth market for clinical trials within the Middle East, a…
Read More
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers – Pharmaceutical Technology
The landscape of oncology drug development is undergoing a profound transformation, increasingly centered on precision immunotherapies where biomarker-defined patient populations…
Read More
